SK Capital to acquire Apotex

Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world.

Financial terms of the transaction have it been disclosed. Apotex currently produces more than 300 generic pharmaceuticals in around 4000 dosages. Globally, the company has the capacity to produce 24 billion tablets and capsules per year, and has around 8,000 employees. It operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico and India.

“Apotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand. We feel incredibly privileged to have the opportunity to support Apotex with our deep experience in the pharmaceutical sector as it continues to research, develop and produce safe and affordable medicines for patients in Canada, the United States and around the world,” said Aaron Davenport, managing director at SK Capital.